Drug Profile
BST 1003
Latest Information Update: 07 Apr 2004
Price :
$50
*
At a glance
- Originator BioStratum
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases
Most Recent Events
- 07 Apr 2004 Discontinued - Preclinical for Cancer metastases in USA (unspecified route)
- 14 Feb 2001 No-Development-Reported for Cancer metastases in USA (Unknown route)
- 03 May 1997 Preclinical development for Cancer metastases in USA (Unknown route)